A Stanford University study found that Epstein-Barr virus—the thing that causes mono—could trigger virtually every case of lupus. Not some cases. All of them.

"This is the single most impactful finding to emerge from my lab in my entire career," said immunologist William Robinson, who headed the research. "We think it applies to 100 percent of lupus cases."

Bold claim. But the data backs it up.

What They Found

EBV infects B cells, which are immune cells. Most adults carry EBV somewhere in their body after getting exposed at some point in life. The virus usually just sits there, dormant, causing no problems.

People with lupus show a much deeper infection. Among lupus patients, about 1 in 400 B cells are infected with EBV. That's 25 times higher than in healthy people.

In lab tests, the EBV infection flipped a switch in B cells, activating genes that turn them pro-inflammatory. This has the potential "to promote systemic disease-driving autoimmune responses," according to the study led by immunologist Shady Younis.

Translation: the virus reprograms immune cells to attack the body.

Why This Matters

Lupus causes the immune system to mistakenly attack healthy tissue, creating widespread inflammation throughout the body. It can be severe and life-threatening. As of right now, there is no known cure.

Historical records mention lupus way back in 850 CE. Experts didn't officially recognize and describe it until the 19th century. The name comes from the rash it causes, which resembles a wolf's bite—lupus is Latin for wolf.

Despite over a thousand years of documentation, nobody knew what actually caused it. The mystery persisted because lupus is complex, possibly triggered by numerous factors—nutrient deficiencies, genetics, hormones, and infections.

It turns out it might just be one virus all along.

The B Cell Connection

Researchers suspected EBV was linked to lupus for years. The virus infects B cells, and B-cell activity is imbalanced in people with lupus. The problem was, EBV is hard to measure when it hides inside B cells.

Stanford researchers devised a clever sequencing technique to identify which B cells are infected. Using this method, they showed lupus patients have significantly more EBV-infected B cells than people without lupus, especially memory B cells that enable rapid immune responses.

Healthy humans have hundreds of billions of B cells. About 20% are "autoreactive"—primed to produce antibodies and activate killer immune cells. When EBV infects latent B cells, it appears to flip them into a pro-inflammatory state.

"Our findings provide a mechanistic basis for why only a small fraction of EBV-infected individuals develop SLE," the authors conclude.

Most people get EBV and never develop lupus. But those who do might have acquired a more virulent strain or have some genetic susceptibility that makes the infection spread deeper.

The Treatment Connection

The mechanism is supported by recent immunotherapy for lupus that hunts down and replaces faulty B cells. It has showed remarkable benefits in clinical trials, achieving remission-like outcomes.

If EBV-infected B cells drive lupus, replacing them makes sense as a treatment approach. The therapy has worked. Now researchers understand why.

Guy Gorochov, a virologist from Sorbonne University who wasn't involved in the study, called the work "impressive" but cautioned it's "not the final paper about lupus." Still, he said "they've done a lot and developed an interesting concept."

What This Could Mean

The discovery might explain lupus's seemingly random cycles of flaring and settling. If viral activity in infected B cells fluctuates, inflammation levels would follow.

It could also be relevant to other autoimmune conditions linked to EBV: multiple sclerosis, long COVID, myalgic encephalomyelitis/chronic fatigue syndrome. If EBV triggers lupus through this mechanism, similar processes might drive other autoimmune diseases.

The Bigger Picture

Lupus has been a "cruel mystery" for over a millennium. Experts knew it was autoimmune. They knew B cells were involved. Suspected infections played a role. But researchers couldn't pin down the actual cause.

Now Stanford researchers are saying it's EBV in basically every case. That's a massive claim with huge implications for treatment and prevention.

If they're right—and the 25x infection rate in lupus patients suggests they might be—it changes everything. Lupus goes from mysterious autoimmune condition with unknown cause to viral-triggered disease with a specific mechanism.

That opens doors for targeted treatments. Maybe antivirals that suppress EBV. Maybe vaccines preventing the infection from taking hold. Maybe therapies that reverse the B-cell reprogramming the virus causes.

The immunotherapy already showing promise demonstrates that replacing infected B cells works. Understanding why they're dysfunctional in the first place makes developing better treatments possible.

Not the Final Answer

One study doesn't solve a thousand-year-old mystery completely. But for the first time, researchers have a clear mechanistic explanation for how lupus might start and why it behaves the way it does. That's progress after centuries of uncertainty.

Did you find this information useful? Feel free to bookmark or to post to your timeline to share with your friends.